Global Bipolar Disorders Treatment Market Procedure Techniques, Methodology and Overall Business Outloo

Global Bipolar Disorders Treatment Market Research Report: Information by Drug Type (Mood Stabilizer, Anticonvulsant, Antipsychotic Drug, and Antidepressant Drug), Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Monoamine Oxidase Inhibitors, Beta Blockers, and Tricyclic Antidepressant Drug), End User (Hospitals and Clinics, Multispecialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025

Global Market - Overview

The global bipolar disorders and treatment market is growing with the rapid pace; mainly due to the increasing stress in life. According to a recent study report published by the Market Research Future, The global bipolar disorders and treatment market is booming and expected to gain prominence over the forecast period growing rapidly .The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022). 

Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/1566

Bipolar disorder, called manic depression, which is a mental health condition that causes extreme mood swings includes emotional highs (mania or hypomania) and lows (depression). There are several types of bipolar disorder which includes bipolar I disorder, bipolar II disorder and others. Bipolar I is considered by one or more manic episodes or mixed episodes. Typically a person will experience periods of depression as well. Moreover, bipolar I disorder is marked by extreme manic episodes. Bipolar II disorder are generally diagnosed after one or more major depressive episodes and at least one episode of hypomania, with possible periods of level mood between episodes.

 

 Global Bipolar Disorders and Treatment Market   - Competitive Analysis

 

AstraZeneca (U.K), Bristol-Myers Squibb (U.S), Eli Lilly and Company (U.S), GlaxoSmithKline PLC (U.K), Allergan (U.S), Janssen Pharmaceuticals (Belgium), Dainippon Sumitomo Pharma Co., Ltd (Japan), Lundbeck (Denmark), Abbott (U.S.), Cephalon Inc. (Teva Phamaceuticals), Dainippon Sumitomo Pharma Co. Ltd., Forest Laboratories Inc. (U.S.), Gedeon Richter PLC (Hungary), Otsuka America Pharmaceutical Inc., (U.S.) Repligen Corporation, (U.S.) and Pfizer Inc. (U.S.)  are some of the prominent players at the forefront of competition in the Global Bipolar Disorders and Treatment Market and are profiled in MRFR Analysis.

 

July, 2017- Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced ABILIFY MAINTENA (Aripiprazole) injectable suspension whcih is approved by U.S. FDA for maintenance monotherapy treatment of Bipolar I disorder. According to otsuka company reports ABILIFY MAINTENA is a once a monthly injectable formulation for intramuscular and has been co-developed and co-commercialized with Lundbeck. Based on Phase 3 study data, ABILIFY MAINTENA delayed the time to recurrence of any mood episode in adult patients experiencing a manic episode at screening compared to placebo.

 

March, 2016- Allergan announced availability of VRAYLAR (cariprazine) for treatment of bipolar mania and schizophrenia in adults. VRAYLAR is an oral tablet, approved for the acute treatment of adult patients with manic or associated with bipolar I disorder, with a recommended dose range of 3 to 6 mg/day and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5 to 6 mg/day. According Allergen company reports, bipolar I disorder, and schizophrenia are among the most challenging mental health disorders to manage, and together affect approximately 8.5 million adults in the United States. However, treatment for both illnesses is often complicated by high rates of relapse and a high degree of variability in disease course and severity, as well as patient symptoms and response to treatment.

 

August, 2015- Allergan Successfully completed Naurex acquisition. This acquisition adds potential breakthrough treatments for depression and enhances company's World-class position in mental health. The two lead products Rapastinel (GLYX-13) and NRX-1074 demonstrated rapid action and robust efficacy in Phase 2 Studies in major depressive disorder. According to Allergan company reports, Naurex's unique pipeline includes GLYX-13 and NRX-1074, two compounds that utilize NMDA modulation as a potential new approach to the treatment of Major Depressive Disorder (MDD), a disease that can lead to suicidality among the most severe patients. Moreover, the growing number of unregulated clinics to treat severe depression with off-label medicines is indicative of the desperate need for new treatment options for patients with depression.

Access Report Details @  https://www.marketresearchfuture.com/reports/bipolar-disorders-treatment-market-1566

The report for Global market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Global Bipolar Disorders and Treatment Market   - Regional Analysis

North America dominates the global bipolar disorder and treatment market owing to increased awareness about bipolar disorder in the region and presence of major market players. The U.S. represents the largest market for bipolar disorder followed by Canada in North America region.

According to the National Institute of Mental Health (NIMH), bipolar disorder affects more than 5.7 million adults (about 3 % of the population) in the United States each year. The typical age is the late teens or early 20s, and a history of depression is common in people diagnosed with bipolar.

TOC:

1.    Report Prologue    

2.    Market Introduction    

      2.1    Definition    

      2.2    Scope of the Study    

            2.2.1    Research Objective    

            2.2.2    Assumptions    

            2.2.3    Limitations    

3.    Research Methodology

      3.1    Introduction

      3.2    Primary Research    

      3.3    Secondary research

      3.4    Market Size Estimation

TOC…Continued

Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/1566

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com